secwatch.observer — SEC 8-K summary
======================================

Issuer:     Editas Medicine, Inc. (EDIT)
CIK:        0001650664
Form:       8-K
Filed at:   2022-04-14T23:59:59+00:00
Accession:  0001558370-22-005418
Event type: leadership
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Editas Medicine appoints Gilmore O'Neill as President and CEO, effective June 1, 2022
--------------------------------------------------------------------------------

- Gilmore O'Neill, former EVP of R&D at Sarepta, succeeds James Mullen as CEO; Mullen becomes Executive Chair.
- O'Neill receives $625K base salary, 60% target bonus, and equity valued at ~$11M (options + RSUs + performance RSUs).
- Mullen's base remains $655K through Dec 2022, then drops to $327.5K for part-time Executive Chair from Jan 2023.
- O'Neill appointed to Board as class II director until 2024 annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650664/000155837022005418/0001558370-22-005418-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650664/000155837022005418/edit-20220412x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-005418

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer